Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8586551 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jul, 2023
(5 months from now) | |
US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(4 years from now) | |
US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8586551
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(11 months from now) | |
US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(4 years from now) | |
US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
US7906489
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(4 years from now) | |
US8859510
(Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
US7378508
(Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(5 years from now) | |
US7863249
(Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(11 years from now) | |
US9808530
(Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jan 24, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
Pediatric Exclusivity (PED) | Jul 24, 2023 |
Market Authorisation Date: 27 May, 2011
Treatment: Treatment of microbial infections; Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic